• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
InterMune, Inc. (ITMN) - Financial and Strategic SWOT Analysis Review - Product Image

InterMune, Inc. (ITMN) - Financial and Strategic SWOT Analysis Review

  • ID: 1291966
  • April 2014
  • 42 pages
  • GlobalData

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pharmasset, Inc
  • Tibotec BVBA
  • MORE

InterMune, Inc. (ITMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list READ MORE >

FEATURED COMPANIES

  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pharmasset, Inc
  • Tibotec BVBA
  • MORE

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 - About the Company
InterMune, Inc. - Key Facts
InterMune, Inc. - Key Employees
InterMune, Inc. - Key Employee Biographies
InterMune, Inc. - Major Products and Services
InterMune, Inc. - Pharmaceutical Pipeline Products Data
InterMune, Inc., Pipeline Products by Therapy Area
InterMune, Inc., Pipeline Products by Development Phase
InterMune, Inc. - History
InterMune, Inc. - Company Statement
InterMune, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
InterMune, Inc. - Business Description
InterMune, Inc. - SWOT Analysis
SWOT Analysis - Overview
InterMune, Inc. - Strengths
Strength - Research and Development Activities
Strength - Lead Product Candidate: Pirfenidone
Strength - Patent Portfolio
InterMune, Inc. - Weaknesses
Weakness - History of Losses
Weakness - Revenue Concentration
InterMune, Inc. - Opportunities
Opportunity - Changing Demographics
Opportunity - Biotech Focus
InterMune, Inc. - Threats
Threat - Delay in the Planned Clinical Trials
Threat - Uncertain R&D Outcome
Threat - Tightening of the FDA’s Regulatory Oversight
InterMune, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
InterMune, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
InterMune, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
InterMune, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
InterMune, Inc., Recent Developments
Feb 28, 2014: InterMune Announces Support for First Ever European Patient Charter on Idiopathic Pulmonary Fibrosis
Jan 09, 2014: InterMune Reports Preliminary Fourth Quarter 2013 Esbriet Revenue and Recent Business Highlights
Jan 06, 2014: InterMune To Present At J. P. Morgan Healthcare Conference
Dec 10, 2013: InterMune Announces Support of The Pulmonary Fibrosis Foundation Care Center Network and Patient Registry Initiative
Oct 30, 2013: InterMune Reports Third Quarter 2013 Financial Results And Business Highlights
Oct 23, 2013: InterMune To Release Third Quarter Financial Results On October 30
Sep 24, 2013: Andrew Powell Joins InterMune As Executive Vice President And General Counsel
Jul 17, 2013: InterMune To Release Second Quarter Financial Results On July 24
Jul 02, 2013: InterMune To Present At JMP Securities Healthcare Conference
Apr 30, 2013: EMA Receives Interim Decisions Of General Court Of EU On Access To Clinical And Non-clinical Information
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
InterMune, Inc., Key Facts
InterMune, Inc., Key Employees
InterMune, Inc., Key Employee Biographies
InterMune, Inc., Major Products and Services
InterMune, Inc., Number of Pipeline Products by Therapy Area
InterMune, Inc., Number of Pipeline Products by Development Stage
InterMune, Inc., Pipeline Products By Therapy Area and Development Phase
InterMune, Inc., History
InterMune, Inc., Subsidiaries
InterMune, Inc., Key Competitors
InterMune, Inc., Ratios based on current share price
InterMune, Inc., Annual Ratios
InterMune, Inc., Interim Ratios
InterMune, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
InterMune, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
InterMune, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
InterMune, Inc., Pipeline Products by Therapy Area
InterMune, Inc., Pipeline Products by Development Phase
InterMune, Inc., Performance Chart (2009 - 2013)
InterMune, Inc., Ratio Charts
InterMune, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
InterMune, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014

Pharmasset, Inc
Merck & Co., Inc.
GlaxoSmithKline plc
Gilead Sciences, Inc.
Tibotec BVBA

Note: Product cover images may vary from those shown

RELATED PRODUCTS